Henrik Daub

发表

Cellular targets of gefitinib.

György Kéri, G. Kéri, M. Cotten, 2005, Cancer research.

Global analysis of phosphoproteome regulation by the Ser/Thr phosphatase Ppt1 in Saccharomyces cerevisiae.

Johannes Buchner, J. Buchner, H. Daub, 2012, Journal of proteome research.

Glycoprotein Capture and Quantitative Phosphoproteomics Indicate Coordinated Regulation of Cell Migration upon Lysophosphatidic Acid Stimulation*

H. Daub, Thiemo B. Schreiber, Nina Mäusbacher, 2010, Molecular & Cellular Proteomics.

Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.

H. Daub, Christoph Weber, Thiemo B. Schreiber, 2012, Journal of proteomics.

Signal transduction therapy with rationally designed kinase inhibitors

Doris Hafenbradl, Zoltán Horváth, László Orfi, 2006 .

Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors*

A. Ullrich, H. Daub, Axel Ullrich, 2003, The Journal of Biological Chemistry.

Proteomics Analysis of Protein Kinases by Target Class-selective Prefractionation and Tandem Mass Spectrometry *S

Guido Dieterich, Jürgen Wehland, Lothar Jänsch, 2007, Molecular & Cellular Proteomics.

Large-scale Proteomics Analysis of the Human Kinome

Florian Gnad, Matthias Mann, Jesper V Olsen, 2009, Molecular & Cellular Proteomics.

AXL is a potential target for therapeutic intervention in breast cancer progression.

László Orfi, György Kéri, A. Ullrich, 2008, Cancer research.

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

Ola Engkvist, Zoltán Horváth, László Orfi, 2004, Chemistry & biology.